La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Marksans Pharma Gestione
Gestione criteri di controllo 1/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Mark Saldanha
Amministratore delegato
₹52.2m
Compenso totale
Percentuale dello stipendio del CEO | 92.0% |
Mandato del CEO | 8.8yrs |
Proprietà del CEO | 43.8% |
Durata media del management | Nessun dato |
Durata media del Consiglio di amministrazione | 6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20Analisi delle retribuzioni degli amministratori delegati
Data | Compenso totale | Stipendio | Guadagni aziendali |
---|---|---|---|
Jun 30 2024 | n/a | n/a | ₹3b |
Mar 31 2024 | n/a | n/a | ₹3b |
Dec 31 2023 | n/a | n/a | ₹3b |
Sep 30 2023 | n/a | n/a | ₹3b |
Jun 30 2023 | n/a | n/a | ₹3b |
Mar 31 2023 | ₹52m | ₹48m | ₹3b |
Dec 31 2022 | n/a | n/a | ₹2b |
Sep 30 2022 | n/a | n/a | ₹2b |
Jun 30 2022 | n/a | n/a | ₹2b |
Mar 31 2022 | ₹38m | ₹35m | ₹2b |
Dec 31 2021 | n/a | n/a | ₹2b |
Sep 30 2021 | n/a | n/a | ₹2b |
Jun 30 2021 | n/a | n/a | ₹3b |
Mar 31 2021 | ₹10m | ₹10m | ₹2b |
Dec 31 2020 | n/a | n/a | ₹2b |
Sep 30 2020 | n/a | n/a | ₹2b |
Jun 30 2020 | n/a | n/a | ₹1b |
Mar 31 2020 | ₹10m | ₹10m | ₹1b |
Dec 31 2019 | n/a | n/a | ₹879m |
Sep 30 2019 | n/a | n/a | ₹834m |
Jun 30 2019 | n/a | n/a | ₹780m |
Mar 31 2019 | ₹10m | ₹10m | ₹804m |
Dec 31 2018 | n/a | n/a | ₹666m |
Sep 30 2018 | n/a | n/a | ₹582m |
Jun 30 2018 | n/a | n/a | ₹463m |
Mar 31 2018 | ₹12m | ₹10m | ₹358m |
Compensazione vs Mercato: La retribuzione totale di Mark ($USD 621.97K ) è superiore alla media delle aziende di dimensioni simili nel mercato Indian ($USD 384.17K ).
Compensazione vs guadagni: La retribuzione di Mark è aumentata di oltre il 20% nell'ultimo anno.
AMMINISTRATORE DELEGATO
Mark Saldanha (52 yo)
8.8yrs
Mandato
₹52,161,600
Compensazione
Mr. Mark B. Saldanha, M.Sc. (Maths) & (Stat.)., Dip. (Fin. Mgt.) serves as Promoter and Managing Director of Marksans Pharma Limited, which he joined in October 6, 2005 (alternate name, Glenmark Laboratori...
Membri del Consiglio di amministrazione
Nome | Posizione | Mandato | Compensazione | Proprietà |
---|---|---|---|---|
Non-Independent Executive Chairman & MD | 8.8yrs | ₹52.16m | 43.8% ₹ 43.7b | |
Whole-time Director | 9.9yrs | ₹7.03m | 0.073% ₹ 72.7m | |
Whole-time Director | 5.6yrs | ₹15.25m | Nessun dato | |
Non-Executive Director & Non-Independent | 3yrs | Nessun dato | Nessun dato | |
Non-Executive & Independent Director | 5.1yrs | ₹40.00k | Nessun dato | |
Independent Director | 1.3yrs | Nessun dato | Nessun dato | |
Non-Executive & Independent Director | 12.8yrs | ₹40.00k | Nessun dato | |
Non-Executive Independent Director | 6.4yrs | ₹200.00k | Nessun dato |
6.0yrs
Durata media
53.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di MARKSANS sono considerati esperti (durata media dell'incarico 6 anni).